Studies Validate EKF Diagnostics’ Early Stage Test for Progressive Diabetic Kidney Disease
EKF Diagnostics confirmed the growing weight of independent scientific evidence as validation that soluble TNF Receptors 1 and 2 are strong biomarkers of progressive Diabetic Kidney Disease (DKD). EKF affirms that the markers can be reliably used as diagnostic tests to predict end-stage renal disease (ESRD) up to 10 years in advance.
Since signing an exclusive license agreement for this novel kidney biomarker technology with the prestigious Joslin Diabetes Center (Boston, USA) in 2012, EKF Diagnostics has worked in partnership with Joslin and other key diabetic research centers to further validate clinical utility and develop its sTNFR1 test kit. Both sTNFR1/2 biomarkers have consistently been shown to predict risk of advanced DKD and associated renal decline with greater accuracy than other available clinical tests.
Resulting from this joint work, several studies have now been published. These independently corroborate the original research by Joslin which reported the strong association of elevated sTNFR1/2 levels with the subsequent development of advanced DKD in Type 1 and Type 2 diabetic patients1, 2. This newly published data from eminent European research centers in France (SURDIAGNE Study Group)3 and Finland (FinnDiane Study Group)4 add to the expanding data set underpinning the value of sTNFR1/2 biomarkers; leading to improved diabetic patient management and outcomes through early intervention. Independently, work published from Sweden (PIVUS and ULSAM Study Groups)5 confirm and extend the findings to a community-based setting and to non-diabetic patients.
Other news from the department research and development
